靶向 PPP1R14B 通过 Nrf2/CX3CL1 轴恢复 CD8(+) T 细胞浸润,从而克服前列腺癌的免疫治疗耐药
Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8(+) T-cell infiltration via the Nrf2/CX3CL1 axis.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8(+) T-cell infiltration via the Nrf2/CX3CL1 axis.
A generalizable covalent car-t platform for solid tumors enabled by oncolytic adenovirus-delivered artificial antigens.
本研究通过将共价 SpyCatcher CAR-T 细胞与递送 SpyTag 的 OAD 相结合,建立了一个用于实体瘤免疫治疗的模块化平台。通过将肿瘤识别与内源性抗原表达解耦,该方法提供了一种可推广的策略,以克服实体瘤中的抗原异质性和肿瘤特异性靶点稀缺的问题。
Role of PICK1 in prostate cancer: Modulating epithelial-mesenchymal transition and immune escape through activation of UNC5A.
PICK1 通过激活 UNC5A 阻碍 PC 细胞的 EMT 和免疫逃逸。
CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment.
这些发现凸显了 CXCR2 作为 NEPC 一个有前景的免疫治疗靶点,并强调了其在转化医学中的相关性。
Current status, prospects, and challenges of cell therapy for urological tumors.
An Integrative Methylation-Metabolism Gene Signature Defines Prognosis and Immunosuppressive Microenvironment in Prostate Cancer.
Phenylalanine Hydroxylase as a Prognostic Marker in Pancreatic Cancer: Insights into Tumor Metabolism and Immune Microenvironment.
本研究首次揭示 PAH 作为代谢性免疫调节因子及术后 PC 患者的独立预后因素。PAH 可能通过改变肿瘤微环境影响前列腺癌的结局。
A fatty acid metabolism-based deep learning model predicts biochemical recurrence and identifies NUDT19 as a candidate metabolic factor in prostate ca
本研究建立了一种基于脂肪酸代谢的深度学习模型用于 BCR 预测,并将 NUDT19 鉴定为与脂质代谢重塑和 PCa 进展相关的候选代谢调节因子。
MEMBER ACCOUNT
登录成功会直接打开下一页。